Latest Drug Development News

Page 1 of 29
Vectus Biosystems has received supportive written FDA feedback on VB0004, reducing uncertainty around the drug candidate’s manufacturing, nonclinical and planned clinical development package. The company will now incorporate the guidance into an IND application for a Phase Ib/IIa study in IPF patients in Australia.
Ada Torres
Ada Torres
16 Nov 2026
Charles River Laboratories will pay about US$470 million in cash for Frontage’s bioanalysis and DMPK operations in Pennsylvania, with a further US$75 million tied to performance. The proposed acquisition expands Charles River’s clinical testing capabilities but will initially be neutral to non-GAAP earnings per share.
Ada Torres
Ada Torres
9 Nov 2026
Biotron CEO and executive director Glenn Gilbert has started more than two months ahead of schedule, immediately taking charge of a strategic review centred on SedRx. The review will also test development priorities, capital allocation and partnering options across the company’s drug portfolio.
Ada Torres
Ada Torres
9 Nov 2026
Pfizer has lifted its 2026 revenue and adjusted earnings guidance after a quarter in which newer and acquired medicines grew strongly enough to offset steep declines in COVID-19 products. Overall revenue was flat, while reported net income fell 8%.
Victor Sage
Victor Sage
4 Nov 2026
PYC Therapeutics has moved all four RNA drug programs towards their next development milestones, while reporting $655 million in cash and treasury investments at 30 September. The company’s standalone cash balance covers just 1.13 quarters, making its liquid investment portfolio central to the stated funding runway through 2030.
Ada Torres
Ada Torres
29 Oct 2026
Dimerix has more than doubled its cash balance after an Everest Medicines licensing payment and a drawdown from a secured funding facility. The ASX-listed biotech is also advancing its fully recruited Phase 3 trial while preparing a second kidney drug for Phase 2 testing.
Ada Torres
Ada Torres
29 Oct 2026
New research from the NEPTUNE cohort has strengthened the biological rationale for Dimerix’s DMX-200 kidney drug, linking CCR2 activity and urinary MCP-1 levels with poorer outcomes in FSGS. The findings support the drug’s mechanism, but do not yet demonstrate Phase 3 efficacy.
Ada Torres
Ada Torres
23 Oct 2026
Argent BioPharma ended the September quarter with just A$11,000 in cash after A$734,000 of operating outflows, despite retaining A$7.4 million of unused convertible financing capacity. The company is simultaneously expanding its commercial portfolio through NLC antiviral rights and a CannEpil veterinary programme.
Victor Sage
Victor Sage
23 Oct 2026
Racura Oncology says both Phase 1 RC220 programs have cleared their opening dose cohorts without dose-limiting toxicities, while its Korean expansion broadens the CPACS trial. The company ended September with $30.7 million in cash, which management says funds committed activities into mid-2028.
Victor Sage
Victor Sage
22 Oct 2026
Vectus Biosystems has secured a pre-IND Type B meeting with the FDA for its lead IPF drug candidate VB0004. The regulator’s written feedback, expected by mid-November, should clarify the next US development steps but does not yet authorise clinical trials.
Ada Torres
Ada Torres
30 Sept 2026
TrivarX has made Stabl-Im its central development bet, but the ASX-listed health technology company also reported an $8.76 million FY2026 loss and an auditor-flagged material uncertainty over its ability to continue without further funding. The planned Phase 1 study remains subject to regulatory, ethics and operational clearances.
Ada Torres
Ada Torres
29 Sept 2026
Argent BioPharma has secured exclusive commercialisation rights to selected Tollovir, Tollovid and NutraVir antiviral products in a worldwide deal excluding China. The agreement adds a new commercial pillar alongside CimetrA®, but does not itself grant pharmaceutical development rights or establish clinical efficacy.
Victor Sage
Victor Sage
29 Sept 2026

Browse the archive

Full archive